Company & Sponsor Intelligence
Amgen
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials6
Recruiting4
Completed2
Countries2
Therapeutic footprint
depressionmigraine_headachemultiple_sclerosisout_of_scope
Indexed studies
NCT06180278Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)
multiple_sclerosis · United StatesPHASE4
multiple_sclerosis · United StatesPHASE4
NCT03927144Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients
migraine_headache · United StatesPHASE4
migraine_headache · United StatesPHASE4
NCT03284879Post-Marketing Surveillance Study of OTEZLA
depression · JapanCOMPLETED
depression · JapanCOMPLETED
NCT05549258Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder
multiple_sclerosis · United StatesPHASE2
multiple_sclerosis · United StatesPHASE2
NCT07684235Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
out_of_scope · United StatesPHASE3
out_of_scope · United StatesPHASE3
NCT07614776A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
out_of_scope · United StatesPHASE3
out_of_scope · United StatesPHASE3
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →